T-cell lymphoma test accuracy study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks how accurate a new lab test is at finding signs of T-cell lymphoma in tissue samples. It uses stored samples from people who had or were suspected of having this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older when the sample was taken.
- Your stored tissue sample must be in a special block (FFPE) with at least 8 thin slices.
- If you had T-cell lymphoma or a related blood disorder, your sample can be used.
- If you were suspected of having T-cell lymphoma but tested negative, your sample can also be used.
- Your sample cannot have been preserved with alcohol-based solutions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
This study, run by Massachusetts General Hospital, is collecting information from people around the world who have certain types of T-cell or NK-cell lymphoma. It aims to learn more about these cancers and how they are managed.
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Hear when a new T-Cell Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.